Symbols / OKUR Stock $3.16 -5.39% OnKure Therapeutics, Inc.
OKUR (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Ratings
Current target
$3.16
Low
$11.00
High
$30.00
Mean
$20.20
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-16 | main | HC Wainwright & Co. | Buy → Buy | $27 |
| 2025-08-26 | reit | HC Wainwright & Co. | Buy → Buy | $34 |
| 2025-03-18 | main | HC Wainwright & Co. | Buy → Buy | $34 |
| 2025-03-11 | main | Oppenheimer | Outperform → Outperform | $30 |
| 2025-01-28 | init | Jones Trading | — → Buy | $32 |
| 2024-12-05 | init | Leerink Partners | — → Outperform | $33 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2024-10-10 | init | Oppenheimer | — → Outperform | $35 |
- ADAR1 entities and Daniel Schneeberger report 6.0% of OnKure (NASDAQ: OKUR) - Stock Titan Sat, 16 May 2026 00
- OnKure Therapeutics (OKUR) Receives a Rating Update from a Top Analyst - The Globe and Mail Mon, 11 May 2026 02
- Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite Risky - Yahoo Finance ue, 19 Aug 2025 07
- What date does OnKure Therapeutics, Inc.'s (OKUR) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research hu, 30 Apr 2026 07
- OnKure bets on 2 PI3K drugs for breast cancer and vascular anomalies - Stock Titan ue, 05 May 2026 07
- OKUR Shares Face Turbulence Amid Financial Downturn - StocksToTrade Sat, 28 Mar 2026 07
- TradingKey - TradingKey ue, 12 May 2026 13
- Oppenheimer reiterates OnKure stock rating on pipeline shift - Investing.com Fri, 27 Mar 2026 07
- Unprecedented Gains: OKUR Clinches Pivotal Industry Deal - timothysykes.com Fri, 27 Mar 2026 07
- OnKure Therapeutics (OKUR) Stock Bollinger Bands (Risk Aversion) 2026-04-20 - Expert Verified Trades - UBND thành phố Hải Phòng Mon, 20 Apr 2026 15
- Is OnKure Therapeutics (NASDAQ:OKUR) In A Good Position To Deliver On Growth Plans? - simplywall.st Wed, 23 Jul 2025 07
- OnKure to sell $150M in stock to fund drug development - Daily Camera Sat, 28 Mar 2026 07
- Should I buy OnKure Therapeutics, Inc. (OKUR) - Zacks Investment Research hu, 16 Apr 2026 07
- [EFFECT] OnKure Therapeutics, Inc. SEC Filing - Stock Titan Mon, 04 May 2026 07
- Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT) - The Globe and Mail hu, 07 May 2026 12
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
62.95
+15.75%
|
54.39
+47.25%
|
36.93
+24.08%
|
29.77
|
| Research And Development |
|
48.26
+10.20%
|
43.80
+36.37%
|
32.12
+24.18%
|
25.86
|
| Selling General And Administration |
|
14.69
+38.70%
|
10.59
+119.78%
|
4.82
+23.44%
|
3.90
|
| General And Administrative Expense |
|
14.69
+38.70%
|
10.59
+119.78%
|
4.82
+23.44%
|
3.90
|
| Other Gand A |
|
14.69
+38.70%
|
10.59
+119.78%
|
4.82
+23.44%
|
3.90
|
| Total Expenses |
|
62.95
+15.75%
|
54.39
+47.25%
|
36.93
+24.08%
|
29.77
|
| Operating Income |
|
-62.95
-15.75%
|
-54.39
-47.25%
|
-36.93
-24.08%
|
-29.77
|
| Total Operating Income As Reported |
|
-62.95
-15.75%
|
-54.39
-47.25%
|
-36.93
-24.08%
|
-29.77
|
| EBITDA |
|
-58.68
-13.47%
|
-51.71
-48.80%
|
-34.75
-18.29%
|
-29.38
|
| Normalized EBITDA |
|
-58.68
-13.47%
|
-51.71
-48.80%
|
-34.75
-18.29%
|
-29.38
|
| Reconciled Depreciation |
|
0.83
+25.38%
|
0.66
+18.21%
|
0.56
+44.70%
|
0.39
|
| EBIT |
|
-59.51
-13.63%
|
-52.37
-48.32%
|
-35.31
-18.63%
|
-29.77
|
| Net Income |
|
-59.52
-12.99%
|
-52.67
-49.17%
|
-35.31
-19.65%
|
-29.51
|
| Pretax Income |
|
-59.52
-12.99%
|
-52.67
-49.17%
|
-35.31
-19.65%
|
-29.51
|
| Net Non Operating Interest Income Expense |
|
3.43
+100.41%
|
1.71
+5.55%
|
1.62
+538.98%
|
0.25
|
| Interest Expense Non Operating |
|
0.01
-97.33%
|
0.30
|
0.00
|
—
|
| Net Interest Income |
|
3.43
+100.41%
|
1.71
+5.55%
|
1.62
+538.98%
|
0.25
|
| Interest Expense |
|
0.01
-97.33%
|
0.30
|
0.00
|
—
|
| Interest Income Non Operating |
|
3.44
+70.94%
|
2.01
+24.03%
|
1.62
+538.98%
|
0.25
|
| Interest Income |
|
3.44
+70.94%
|
2.01
+24.03%
|
1.62
+538.98%
|
0.25
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-59.52
-12.99%
|
-52.67
-49.17%
|
-35.31
-19.65%
|
-29.51
|
| Net Income From Continuing Operation Net Minority Interest |
|
-59.52
-12.99%
|
-52.67
-49.17%
|
-35.31
-19.65%
|
-29.51
|
| Net Income From Continuing And Discontinued Operation |
|
-59.52
-12.99%
|
-52.67
-49.17%
|
-35.31
-19.65%
|
-29.51
|
| Net Income Continuous Operations |
|
-59.52
-12.99%
|
-52.67
-49.17%
|
-35.31
-19.65%
|
-29.51
|
| Normalized Income |
|
-59.52
-12.99%
|
-52.67
-49.17%
|
-35.31
-19.65%
|
-29.51
|
| Net Income Common Stockholders |
|
-59.52
-12.99%
|
-52.67
-49.17%
|
-35.31
-19.65%
|
-29.51
|
| Diluted EPS |
|
—
|
-15.28
-477.23%
|
-2.65
-19.65%
|
-2.21
|
| Basic EPS |
|
—
|
-15.28
-477.23%
|
-2.65
-19.65%
|
-2.21
|
| Basic Average Shares |
|
—
|
3.45
-74.16%
|
13.34
+0.00%
|
13.34
|
| Diluted Average Shares |
|
—
|
3.45
-74.16%
|
13.34
+0.00%
|
13.34
|
| Diluted NI Availto Com Stockholders |
|
-59.52
-12.99%
|
-52.67
-49.17%
|
-35.31
-19.65%
|
-29.51
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
62.12
-45.94%
|
114.91
+221.56%
|
35.73
+123.35%
|
16.00
|
| Current Assets |
|
60.84
-46.16%
|
113.00
+234.67%
|
33.77
+147.86%
|
13.62
|
| Cash Cash Equivalents And Short Term Investments |
|
59.05
-46.69%
|
110.76
+270.74%
|
29.88
+158.82%
|
11.54
|
| Cash And Cash Equivalents |
|
59.05
-46.69%
|
110.76
+270.74%
|
29.88
+158.82%
|
11.54
|
| Prepaid Assets |
|
—
|
2.24
-42.37%
|
3.89
+213.71%
|
1.24
|
| Other Current Assets |
|
1.79
-20.21%
|
2.24
+221.20%
|
0.70
-16.90%
|
0.84
|
| Total Non Current Assets |
|
1.28
-32.88%
|
1.90
-3.25%
|
1.97
-17.17%
|
2.38
|
| Net PPE |
|
1.00
-44.01%
|
1.79
-6.02%
|
1.91
-6.69%
|
2.05
|
| Gross PPE |
|
2.47
-15.37%
|
2.91
+13.17%
|
2.58
+12.20%
|
2.29
|
| Accumulated Depreciation |
|
-1.46
-30.56%
|
-1.12
-68.27%
|
-0.67
-168.15%
|
-0.25
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.32
-8.31%
|
0.35
+15.95%
|
0.30
+68.16%
|
0.18
|
| Other Properties |
|
1.06
-28.41%
|
1.48
+24.58%
|
1.18
+6.47%
|
1.11
|
| Leases |
|
1.09
+0.00%
|
1.09
+0.00%
|
1.09
+8.57%
|
1.00
|
| Other Non Current Assets |
|
0.27
+150.46%
|
0.11
+87.93%
|
0.06
-82.37%
|
0.33
|
| Total Liabilities Net Minority Interest |
|
5.93
-46.45%
|
11.08
-91.95%
|
137.58
+95.37%
|
70.42
|
| Current Liabilities |
|
5.92
-43.77%
|
10.53
+44.54%
|
7.29
+31.45%
|
5.54
|
| Payables And Accrued Expenses |
|
2.68
-60.72%
|
6.82
+25.99%
|
5.41
+37.59%
|
3.94
|
| Payables |
|
1.43
-51.72%
|
2.97
-13.14%
|
3.42
+35.60%
|
2.52
|
| Accounts Payable |
|
1.43
-51.72%
|
2.97
-13.14%
|
3.42
+35.60%
|
2.52
|
| Current Accrued Expenses |
|
1.25
-67.66%
|
3.85
+92.94%
|
2.00
+41.13%
|
1.42
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
2.69
-15.13%
|
3.17
+90.80%
|
1.66
+14.22%
|
1.46
|
| Current Debt And Capital Lease Obligation |
|
0.55
+2.43%
|
0.54
+157.69%
|
0.21
+37.75%
|
0.15
|
| Current Capital Lease Obligation |
|
0.55
+2.43%
|
0.54
+157.69%
|
0.21
+37.75%
|
0.15
|
| Total Non Current Liabilities Net Minority Interest |
|
0.01
-97.81%
|
0.55
-99.58%
|
130.29
+100.83%
|
64.88
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
-100.00%
|
0.55
+17.81%
|
0.47
-4.12%
|
0.49
|
| Long Term Capital Lease Obligation |
|
0.00
-100.00%
|
0.55
+17.81%
|
0.47
-4.12%
|
0.49
|
| Other Non Current Liabilities |
|
0.01
|
—
|
—
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
0.00
-100.00%
|
129.82
+101.63%
|
64.39
|
| Stockholders Equity |
|
56.18
-45.89%
|
103.83
+201.95%
|
-101.84
-87.15%
|
-54.42
|
| Common Stock Equity |
|
56.18
-45.89%
|
103.83
+201.95%
|
-101.84
-87.15%
|
-54.42
|
| Capital Stock |
|
0.00
+0.00%
|
0.00
|
0.00
-100.00%
|
0.00
|
| Common Stock |
|
0.00
+0.00%
|
0.00
|
0.00
-100.00%
|
0.00
|
| Share Issued |
|
13.67
+2.45%
|
13.35
+0.06%
|
13.34
+0.00%
|
13.34
|
| Ordinary Shares Number |
|
13.67
+2.45%
|
13.35
+0.06%
|
13.34
+0.00%
|
13.34
|
| Additional Paid In Capital |
|
270.42
+4.59%
|
258.55
+123608.61%
|
0.21
-92.13%
|
2.65
|
| Retained Earnings |
|
-214.24
-38.47%
|
-154.72
-51.61%
|
-102.05
-78.80%
|
-57.07
|
| Total Equity Gross Minority Interest |
|
56.18
-45.89%
|
103.83
+201.95%
|
-101.84
-87.15%
|
-54.42
|
| Total Capitalization |
|
56.18
-45.89%
|
103.83
+201.95%
|
-101.84
-87.15%
|
-54.42
|
| Working Capital |
|
54.92
-46.41%
|
102.47
+286.97%
|
26.48
+227.69%
|
8.08
|
| Invested Capital |
|
56.18
-45.89%
|
103.83
+201.95%
|
-101.84
-87.15%
|
-54.42
|
| Total Debt |
|
0.55
-49.40%
|
1.08
+60.98%
|
0.67
+5.81%
|
0.64
|
| Capital Lease Obligations |
|
0.55
-49.40%
|
1.08
+60.98%
|
0.67
+5.81%
|
0.64
|
| Net Tangible Assets |
|
56.18
-45.89%
|
103.83
+201.95%
|
-101.84
-87.15%
|
-54.42
|
| Tangible Book Value |
|
56.18
-45.89%
|
103.83
+201.95%
|
-101.84
-87.15%
|
-54.42
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-51.83
-1.39%
|
-51.12
-47.97%
|
-34.55
-28.17%
|
-26.95
|
| Cash Flow From Continuing Operating Activities |
|
-51.83
-1.39%
|
-51.12
-47.97%
|
-34.55
-28.17%
|
-26.95
|
| Net Income From Continuing Operations |
|
-59.52
-12.99%
|
-52.67
-49.17%
|
-35.31
-19.65%
|
-29.51
|
| Depreciation Amortization Depletion |
|
0.83
+25.38%
|
0.66
+18.21%
|
0.56
+44.70%
|
0.39
|
| Depreciation |
|
0.83
+25.38%
|
0.66
+18.21%
|
0.56
+44.70%
|
0.39
|
| Depreciation And Amortization |
|
0.83
+25.38%
|
0.66
+18.21%
|
0.56
+44.70%
|
0.39
|
| Other Non Cash Items |
|
—
|
0.26
|
—
|
—
|
| Stock Based Compensation |
|
11.63
+156.80%
|
4.53
+2176.38%
|
0.20
+314.58%
|
0.05
|
| Operating Gains Losses |
|
0.01
-88.89%
|
0.05
|
—
|
—
|
| Gain Loss On Investment Securities |
|
—
|
0.05
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
0.01
|
0.00
|
—
|
—
|
| Change In Working Capital |
|
-4.78
-20.95%
|
-3.95
-65966.67%
|
0.01
-99.72%
|
2.12
|
| Change In Prepaid Assets |
|
0.29
-87.19%
|
2.26
+250.70%
|
-1.50
-350.90%
|
-0.33
|
| Change In Payables And Accrued Expense |
|
-4.54
+23.32%
|
-5.93
-446.00%
|
1.71
-35.36%
|
2.65
|
| Change In Other Current Liabilities |
|
-0.52
-86.48%
|
-0.28
-33.81%
|
-0.21
-8.25%
|
-0.19
|
| Investing Cash Flow |
|
-0.05
-100.29%
|
15.87
+6552.44%
|
-0.25
+78.31%
|
-1.13
|
| Cash Flow From Continuing Investing Activities |
|
-0.05
-100.29%
|
15.87
+6552.44%
|
-0.25
+78.31%
|
-1.13
|
| Net PPE Purchase And Sale |
|
-0.05
+11.54%
|
-0.05
+78.86%
|
-0.25
+78.31%
|
-1.13
|
| Purchase Of PPE |
|
-0.05
+11.54%
|
-0.05
+78.86%
|
-0.25
+78.31%
|
-1.13
|
| Capital Expenditure |
|
-0.05
+11.54%
|
-0.05
+78.86%
|
-0.25
+78.31%
|
-1.13
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
15.93
|
0.00
|
—
|
| Sale Of Investment |
|
0.00
-100.00%
|
15.93
|
0.00
|
—
|
| Financing Cash Flow |
|
0.16
-99.86%
|
116.13
+118.60%
|
53.12
+100.74%
|
26.46
|
| Cash Flow From Continuing Financing Activities |
|
0.16
-99.86%
|
116.13
+118.60%
|
53.12
+100.74%
|
26.46
|
| Net Issuance Payments Of Debt |
|
0.00
-100.00%
|
6.00
|
0.00
|
—
|
| Issuance Of Debt |
|
0.00
-100.00%
|
6.00
|
0.00
|
—
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
6.00
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
0.00
-100.00%
|
6.00
|
0.00
|
—
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
58.91
+90526.15%
|
0.07
-80.88%
|
0.34
|
| Proceeds From Stock Option Exercised |
|
0.24
|
0.00
|
—
|
—
|
| Net Other Financing Charges |
|
-0.08
-100.15%
|
51.22
+7184.65%
|
-0.72
+47.42%
|
-1.38
|
| Changes In Cash |
|
-51.71
-163.93%
|
80.89
+341.20%
|
18.33
+1230.27%
|
-1.62
|
| Beginning Cash Position |
|
110.76
+270.74%
|
29.88
+158.82%
|
11.54
-12.32%
|
13.16
|
| End Cash Position |
|
59.05
-46.69%
|
110.76
+270.74%
|
29.88
+158.82%
|
11.54
|
| Free Cash Flow |
|
-51.87
-1.38%
|
-51.17
-47.07%
|
-34.79
-23.87%
|
-28.09
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
—
|
| Common Stock Issuance |
|
0.00
-100.00%
|
58.91
+90526.15%
|
0.07
-80.88%
|
0.34
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
58.91
+9.39%
|
53.85
+93.42%
|
27.84
|
| Net Preferred Stock Issuance |
|
—
|
0.00
-100.00%
|
53.78
+95.57%
|
27.50
|
| Preferred Stock Issuance |
|
—
|
0.00
-100.00%
|
53.78
+95.57%
|
27.50
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-05-05 View
- 10-Q2026-05-05 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-01 View
- 8-K2026-03-30 View
- 42026-03-24 View
- 42026-03-24 View
- 10-K2026-03-12 View
- 8-K2026-03-12 View
- 42026-01-02 View
- 42026-01-02 View
- 42025-12-23 View
- 42025-12-23 View
- 8-K2025-11-06 View
- 10-Q2025-11-06 View
- 8-K2025-11-06 View
- 42025-10-02 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|